View Older Stories View More Recent Stories

Nov 7, 2022 04:05PM Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
Nov 4, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2022 04:01PM Apellis Pharmaceuticals (APLS) to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
Nov 3, 2022 04:01PM Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
Nov 3, 2022 04:01PM Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
Nov 3, 2022 09:05AM Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
Nov 3, 2022 09:05AM Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
Oct 31, 2022 04:05PM Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
Oct 31, 2022 04:05PM Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
Oct 7, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 7, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 3, 2022 05:49AM Apellis Pharmaceuticals (APLS) Reports Strong 24-Month Phase 3 Post Hoc Results of Pegcetacoplan
Sep 30, 2022 05:30PM Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AA
Sep 30, 2022 05:30PM Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AA
Sep 30, 2022 07:02AM Apellis Pharmaceuticals (APLS) Announces Oral Presentations from Phase 3 DERBY and OAKS Studies at AAO
Sep 30, 2022 07:00AM Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Me
Sep 30, 2022 07:00AM Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Me
Sep 12, 2022 04:05PM Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
Sep 12, 2022 04:05PM Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
Sep 7, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2022 07:00AM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Sep 1, 2022 07:00AM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 24, 2022 08:01AM Apellis Pharmaceuticals (APLS) Reports Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies
Aug 24, 2022 08:00AM Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
Aug 24, 2022 08:00AM Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
Aug 8, 2022 04:05PM Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
Aug 8, 2022 04:05PM Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
Aug 4, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2022 04:05PM Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results
Aug 1, 2022 04:05PM Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results
Jul 19, 2022 07:04AM Apellis Pharmaceuticals (APLS) Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy
Jul 19, 2022 07:00AM Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)
Jul 19, 2022 07:00AM Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)
Jul 14, 2022 10:01AM Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting
Jul 14, 2022 10:01AM Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting
Jul 6, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 6, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 22, 2022 07:00AM Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
Jun 22, 2022 07:00AM Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
Jun 10, 2022 05:34AM Apellis Pharmaceuticals (APLS) and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI
Jun 10, 2022 03:00AM Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
Jun 10, 2022 03:00AM Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
Jun 7, 2022 07:00AM Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
Jun 7, 2022 07:00AM Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
Jun 6, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 6, 2022 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 1, 2022 04:05PM Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
View More Recent Stories View Older Stories